NCT06210737View on ClinicalTrials.gov

A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years

PHASE4CompletedINTERVENTIONAL
Enrollment

621

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

November 13, 2022

Study Completion Date

November 13, 2022

Conditions
Pneumonia
Interventions
BIOLOGICAL

PCV13

3 doses of PCV13 intramuscularly at Months 0, 2, and 4 and a booster dose at Month 10

BIOLOGICAL

PCV13

2 doses of PCV13, and a booster dose

BIOLOGICAL

PCV13

2 doses of PCV13

BIOLOGICAL

PCV13

single dose of PCV13

Trial Locations (1)

210000

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

Sponsors
All Listed Sponsors
lead

Beijing Minhai Biotechnology Co., Ltd

INDUSTRY